Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Cardiol Therapeutics, with a price target of $8.00. T...

Canaccord Genuity Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)

Cardiol Therapeutics Inc. ( ($CRDL) ) has released its Q3 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to i...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDL	$1.08	-0.92%	352.10K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDL	$1.08	-0.9%	352.10K
3
4
5
6

CRDL

CRDL

Dividend Overview

Get Cardiol Therapeutics Inc. Data in Excel

Get Cardiol Therapeutics Inc. Data in Excel